Why the study?
Does post-treatment platelet reactivity predict post-discharge non-CABG-related bleeding in patients with NSTE ACS?
Does post-treatment platelet reactivity predict post-discharge non-CABG-related bleeding in patients with NSTE ACS?
Low post-treatment platelet reactivity (hyper-response to antiplatelet therapy) is associated with a significantly increased risk of post-discharge bleeding in NSTE ACS patients.
Answers are grounded in this paper and cite their sources.
May flag hyper-responders for higher post-discharge bleeding risk in NSTE ACS; leaves open whether reactivity testing should guide therapy.
AIMS: We assessed prospectively the association between occurrence of post-discharge non-CABG-related TIMI major and minor bleeding and post-treatment platelet reactivity in patients with non-ST elevation acute coronary syndrome (NSTE ACS). METHODS AND RESULTS: Five hundred and ninety-seven consecutive patients admitted with NSTE ACS were prospectively included. Between hospital discharge and one month follow-up, we observed 16 (2.7%) non-CABG-related TIMI haemorrhagic complications including five (0.84%) major and 11 (1.8%) minor bleeds. Patients with bleeding had significantly lower post-treatment values of ADP-induced aggregation (43+/-14% versus. 56+/-19%, p=0.002) and platelet reactivity index VASP (43+/-14% versus 54+/-23%; p=0.04) and a trend for lower values of arachidonic acid-induced aggregation (2.4+/-5.4 versus 13+/-21; p=0.27). After stratification by quartiles based on post-treatment ADP-induced platelet aggregation, we identified patients in the first quartile as hyper-responders with very low post-treatment platelet reactivity, below <40%. The risk of TIMI major and minor bleeding was significantly higher in the first quartile of hyper-responders than in the others quartiles: 10 (6.6%) versus six (1.4%), p=0.001. CONCLUSIONS: Our results suggest that assessment of post-treatment platelet reactivity might be used to detect hyper-responders to antiplatelet therapy with higher risk of non-CABG related bleeding and tailor antiplatelet therapy according to both ischaemic and bleeding risk.
No takes yet. Share an insight, caveat, or question.
Cuisset et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: